Humanwell Healthcare (Group) Co Ltd (600079):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Humanwell Healthcare (Group) Co Ltd (600079) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7991
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Humanwell Healthcare (Group) Co Ltd (Humanwell), formerly Wuhan Humanwell Hi-Tech Industry Co Ltd is a pharmaceutical company that offers generic products. The company offers pharmaceutical, medical instrument and reproductive health care products and technologies. Its products include anesthetics, biological products, herbal medicines, CNS medicines, women’s health, anti-infection drugs, medical devices, OTC medicines and other products. Humanwell also provides buflomedil hydrochloride injectable, pantoprazole sodium injectable, omeprazole sodium injectable, phloroglucinol injectable, and simvastatin capsules. The company produces products in the forms of injection, tablets, syrup, granules, capsules, and suspension. It has partnership with other research institutes for investments, commercial distribution and research and development. Humanwell is headquartered in Wuhan, China.

Humanwell Healthcare (Group) Co Ltd (600079) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Humanwell Healthcare (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Ambrx Raises USD45 Million in Venture Financing 13
Private Equity 15
AGIC Capital Acquires Ritedose From Olympus Partners 15
Licensing Agreements 17
Elite Pharma Enters into Licensing Agreement with Epic Pharma for Abuse-Deterrent ELI-200 17
Elite Pharma Enters Into Licensing Agreement With Epic Pharma For Twelve Generic Products 18
Equity Offering 19
Humanwell Healthcare Decreases Size of Private Placement of Shares for USD174 Million 19
Wuhan Humanwell Healthcare Plans Private Placement of Shares for up to USD412.5 Million 20
Wuhan Humanwell Hi-tech Industry Plans For Private Placement Of Shares For Up To US$163 Million 21
Debt Offering 22
Humanwell Healthcare to Raise USD302 Million in Private Placement of Notes 22
Humanwell Healthcare Raises USD150.8 Million in First Tranche of 4.99% Public Offering of Notes Due 2018 23
Humanwell Healthcare to Raise USD296.81 Million in Commercial Paper Offering 24
Humanwell Healthcare Raises USD224 Million in Public Offering of Notes 25
Humanwell Healthcare Plans to Raise USD309 Million in Public Offering of Notes 26
Humanwell Healthcare to Raise up to USD155 Million in Public Offering of Bonds 27
Wuhan Humanwell Announces Public Offering Of Notes Due 2015 For US$95 MIllion 28
Acquisition 29
CSL to Acquire Remaining 20% Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD102 Million 29
Humanwell Healthcare Sells Bio-Pharma Unit for USD53 Million 30
CSL Acquires 80% Equity Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD352 Million 31
Humanwell Healthcare and PuraCap Pharma Acquire 100% Stake in Epic Pharma 32
Humanwell Healthcare Acquires Epic RE Holdco for USD21 Million 34
Humanwell Healthcare Plans to Acquire 70% Stake in Chengdu Kanghong Pharma for USD53 Million 35
Humanwell Healthcare Plans to Sell Shenzhen Biotech Firm for USD36 Million 36
Humanwell Healthcare to Acquire Yichang Sanxia Pharmaceutical for USD71.06 Million 37
Humanwell Healthcare Plans to Acquire 70% Stake in Pharmaceutical Firm for USD40 Million 38
Humanwell Healthcare (Group) Co Ltd – Key Competitors 39
Humanwell Healthcare (Group) Co Ltd – Key Employees 40
Humanwell Healthcare (Group) Co Ltd – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Humanwell Healthcare (Group) Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Humanwell Healthcare (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Ambrx Raises USD45 Million in Venture Financing 13
AGIC Capital Acquires Ritedose From Olympus Partners 15
Elite Pharma Enters into Licensing Agreement with Epic Pharma for Abuse-Deterrent ELI-200 17
Elite Pharma Enters Into Licensing Agreement With Epic Pharma For Twelve Generic Products 18
Humanwell Healthcare Decreases Size of Private Placement of Shares for USD174 Million 19
Wuhan Humanwell Healthcare Plans Private Placement of Shares for up to USD412.5 Million 20
Wuhan Humanwell Hi-tech Industry Plans For Private Placement Of Shares For Up To US$163 Million 21
Humanwell Healthcare to Raise USD302 Million in Private Placement of Notes 22
Humanwell Healthcare Raises USD150.8 Million in First Tranche of 4.99% Public Offering of Notes Due 2018 23
Humanwell Healthcare to Raise USD296.81 Million in Commercial Paper Offering 24
Humanwell Healthcare Raises USD224 Million in Public Offering of Notes 25
Humanwell Healthcare Plans to Raise USD309 Million in Public Offering of Notes 26
Humanwell Healthcare to Raise up to USD155 Million in Public Offering of Bonds 27
Wuhan Humanwell Announces Public Offering Of Notes Due 2015 For US$95 MIllion 28
CSL to Acquire Remaining 20% Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD102 Million 29
Humanwell Healthcare Sells Bio-Pharma Unit for USD53 Million 30
CSL Acquires 80% Equity Stake in Wuhan Zhong Yuan Rui De Biological Products from Humanwell Healthcare Group for USD352 Million 31
Humanwell Healthcare and PuraCap Pharma Acquire 100% Stake in Epic Pharma 32
Humanwell Healthcare Acquires Epic RE Holdco for USD21 Million 34
Humanwell Healthcare Plans to Acquire 70% Stake in Chengdu Kanghong Pharma for USD53 Million 35
Humanwell Healthcare Plans to Sell Shenzhen Biotech Firm for USD36 Million 36
Humanwell Healthcare to Acquire Yichang Sanxia Pharmaceutical for USD71.06 Million 37
Humanwell Healthcare Plans to Acquire 70% Stake in Pharmaceutical Firm for USD40 Million 38
Humanwell Healthcare (Group) Co Ltd, Key Competitors 39
Humanwell Healthcare (Group) Co Ltd, Key Employees 40
Humanwell Healthcare (Group) Co Ltd, Subsidiaries 41

List of Figures
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Humanwell Healthcare (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Humanwell Healthcare (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Humanwell Healthcare (Group) Co Ltd (600079):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bush Industries Inc:企業の戦略・SWOT・財務分析
    Bush Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Bush Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Wesfarmers Limited:企業の戦略・SWOT・財務分析
    Wesfarmers Limited - Strategy, SWOT and Corporate Finance Report Summary Wesfarmers Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • HORNBACH Holding AG & Co. KGaA:企業の戦略・SWOT・財務分析
    HORNBACH Holding AG & Co. KGaA - Strategy, SWOT and Corporate Finance Report Summary HORNBACH Holding AG & Co. KGaA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Nielsen Holdings PLC:企業の戦略・SWOT・財務分析
    Nielsen Holdings PLC - Strategy, SWOT and Corporate Finance Report Summary Nielsen Holdings PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Samsung Electronics Co., Ltd.:企業の戦略・SWOT・財務情報
    Samsung Electronics Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Samsung Electronics Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Alchemia Ltd (ACL)-製薬・医療分野:企業M&A・提携分析
    Summary Alchemia Ltd (Alchemia) is a biopharmaceutical company that focuses on the discovery and development of drugs for the treatment of cancer and respiratory disorders. It sold the worldwide exclusive intellectual property rights to its product, Fondaparinux sodium (a generic version of the anti …
  • Baron Oil Plc (BOIL):企業の財務・戦略的SWOT分析
    Summary Baron Oil Plc (Baron Oil), formerly Gold Oil PLC is an oil and gas exploration and production company. The company identifies and develops crude oil and natural gas interests in Latin America including Peru and Colombia. It holds working interests of Nancy Burdine Maxine oil field, oil and g …
  • Hanesbrands Inc.:企業の戦略・SWOT・財務情報
    Hanesbrands Inc. - Strategy, SWOT and Corporate Finance Report Summary Hanesbrands Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Nihon Kohden Corp (6849)-医療機器分野:企業M&A・提携分析
    Summary Nihon Kohden Corp (Nihon Kohden) is a provider of medical electronic equipment to support treatment in clinical areas of emergency response; testing, diagnosis, treatment, and rehabilitation. Its major products include patient monitors, electroencephalographs, evoked potential and electromyo …
  • Occidental Petroleum Corporation:企業の戦略・SWOT・財務情報
    Occidental Petroleum Corporation - Strategy, SWOT and Corporate Finance Report Summary Occidental Petroleum Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Dominion Energy Inc (D):石油・ガス:M&Aディール及び事業提携情報
    Summary Dominion Energy, Inc. (Dominion), formerly Dominion Resources, Inc., is a producer and transporter of energy. It carries out the generation, transmission and distribution of electricity; transmission, distribution, storage and processing of gas; and LNG import and storage activities. The com …
  • REC Silicon ASA (REC):電力:M&Aディール及び事業提携情報
    Summary REC Silicon ASA (REC Silicon), formerly Renewable Energy Corporation ASA, is a producer of advanced silicon materials, and delivers high-purity polysilicon and silicon gas. Its products find application in the solar and electronics industries in the production of solar panels, flat panel dis …
  • Perrigo Company Plc (PRGO)-医療機器分野:企業M&A・提携分析
    Summary Perrigo Company plc (Perrigo) is an over-the-counter consumer goods and specialty pharmaceutical company. It develops, manufactures and distributes over-the-counter products, generic and prescription pharmaceuticals, specialty pharmaceutical company, nutritional products, active pharmaceutic …
  • Full House Resorts Inc:戦略・SWOT・企業財務分析
    Full House Resorts Inc - Strategy, SWOT and Corporate Finance Report Summary Full House Resorts Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Novacyt SA (ALNOV):企業の財務・戦略的SWOT分析
    Summary Novacyt SA (Novacyt) is a medical device company that develops and markets medical cytology solutions. The company offers oncology and infectious disease diagnostic products. It also sells diagnostic reagents used in LBC, oncology, microbiology, haematology and serology testing. Novacyt deve …
  • The Hain Celestial Group Inc (HAIN):企業の財務・戦略的SWOT分析
    The Hain Celestial Group Inc (HAIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • NARI Technology Development Co Ltd (600406):企業の財務・戦略的SWOT分析
    NARI Technology Development Co Ltd (600406) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Columbia University-製薬・医療分野:企業M&A・提携分析
    Summary Columbia University (CU) is an educational service provider that offers educational and research programs. The university provides educational services and courses through its schools, departments, faculties, centers and institutes. It provides undergraduate and graduate courses in various d …
  • Grasim Industries Ltd (GRASIM):企業の財務・戦略的SWOT分析
    Grasim Industries Ltd (GRASIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Cholamandalam Investment and Finance Company Ltd (CHOLAFIN):企業の財務・戦略的SWOT分析
    Cholamandalam Investment and Finance Company Ltd (CHOLAFIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the comp …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆